Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party
scientific content. Neither the content nor the BenchSci technology and processes for
selection have been evaluated by us; we are providing them as-is and without warranty of any kind,
including for use or application of the Thermo Fisher Scientific products presented.
Description: eBioTY/11.8 recognizes the with CD73 a 69-kDa GPI-anchored cell-surface protein with ecto-5'-nucleotidase activity. Expression on myeloid cells (CD11b) is restricted to the bone marrow. In human CD73 can be induced to secrete a soluble form with IL-2 suggesting a role in mediating activation signals. Differences between human and mouse CD73 have been reported. BALB/c mice have more CD4+CD73+ than CD8+CD73+ while the reciprocal is documented in humans.
CD73 is expressed on a subset of lymphocytes and increases during lymphocyte maturation. Recently it has been found that memory CD4 T cells express and are similar to the uncommitted primed precursor helper cells (Thpp) that can differentiate into Th1 or Th2 cells. Furthermore CD73 has been found on regulatory T cells.
Applications Reported: This eBioTY/11.8 (TY/11.8) antibody has been reported for use in flow cytometric analysis.
Applications Tested: This eBioTY/11.8 (TY/11.8) antibody has been tested by flow cytometric analysis of mouse splenocytes. This can be used at less than or equal to 0.5 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Storage and handling: Use in a sterile environment.
Filtration: 0.2 µm post-manufacturing filtered.
Purity: Greater than 90%, as determined by SDS-PAGE.
Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay.
Aggregation: Less than 10%, as determined by HPLC.
CD73 (Ecto-5-prime-nucleotidase, 5-prime-ribonucleotide phosphohydrolase) catalyzes the conversion at neutral pH of purine 5-prime mononucleotides to nucleosides, the preferred substrate being AMP. CD73 consists of a dimer of 2 identical 70 kDa subunits bound externally to the plasma membrane by a glycosyl phosphatidyl inositol linkage. CD73 is used as a marker of lymphocyte differentiation. Consequently, a deficiency of CD73 occurs in a variety of immunodeficiency diseases. Other forms of 5-prime nucleotidase exist in the cytoplasm and lysosomes and can be distinguished from CD73 by their substrate affinities, requirement for divalent magnesium ion, activation by ATP, and inhibition by inorganic phosphate. The CD73 gene has been localized to 6q14-q21 by immunofluorescence and a study of a panel of human x mouse hybrids that contained fragments of chromosome 6 as translocations. Defects in the CD73 gene can lead to the calcification of joints and arteries, and intestinal tuberculosis. Two transcript variants encoding different isoforms of CD73 have been found.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
5'-NT; 5'-nucleotidase; CD73; Ecto-5'-nucleotidase